Prolia (Denosumab) Adolescent (12, 17) Dosing

Why Denosumab Is Not Approved for Adolescents

The FDA approved denosumab (Prolia, 60 mg SC every 6 months) in 2010 for postmenopausal osteoporosis based on the FREEDOM trial (N=7,868), which enrolled women aged 60 to 90 and demonstrated a 68% reduction in new vertebral fractures over 3 years [1]. The trial population excluded anyone under 18.

Amgen's prescribing information explicitly states that safety and efficacy have not been established in pediatric patients and warns that denosumab may impair bone growth in children with open growth plates. This warning stems from preclinical data: juvenile cynomolgus monkeys given denosumab at doses producing exposures 2.7 to 15 times the adult human exposure showed abnormal growth plates, reduced bone strength, and impaired tooth eruption [2]. In skeletally immature animals, RANKL blockade disrupted the osteoclast-mediated resorption necessary for normal endochondral ossification.

No pharmaceutical sponsor has conducted a registration trial in adolescents. The pediatric evidence that does exist comes from investigator-initiated studies in rare bone diseases, primarily osteogenesis imperfecta (OI), giant cell tumor of bone, and aneurysmal bone cysts.

Off-Label Dosing Protocols in Pediatric Studies

Most published evidence on denosumab in young patients comes from European and Australian centers treating children with osteogenesis imperfecta. Dosing varies widely across institutions because no consensus guideline exists.

Hoyer-Kuhn et al. published a prospective trial of 10 children with OI types I, III, and IV (ages 5 to 11) using a weight-based protocol of 1 mg/kg subcutaneously every 12 weeks [3]. After 48 weeks, lumbar spine areal bone mineral density (aBMD) Z-scores improved by a mean of +0.49, and urinary deoxypyridinoline (a resorption marker) dropped by 56% from baseline. The dosing interval of 12 weeks (rather than the adult 24-week interval) was chosen because pediatric pharmacokinetic modeling predicted faster drug clearance in smaller patients with higher metabolic rates.

A separate German cohort of 4 adolescents aged 12 to 16 used the same 1 mg/kg protocol but extended the interval to every 16 to 24 weeks, reflecting slower drug clearance in larger patients approaching adult body mass [3]. Bone turnover markers suppressed within 48 hours and remained suppressed for approximately 10 to 16 weeks before rebounding.

For giant cell tumor of bone in adolescents, the Chawla et al. phase 2 study used the adult Xgeva dose of 120 mg SC every 4 weeks (with loading doses on days 8 and 15 of cycle 1), though this indication uses a different product (Xgeva, not Prolia) and a different dose rationale [4]. This dose is not transferable to osteoporosis management.

A practical summary of published adolescent protocols:

| Parameter | Younger adolescents (12, 14) | Older adolescents (15, 17) | |---|---|---| | Dose | 1 mg/kg SC | 1 mg/kg SC (up to 60 mg) | | Interval | Every 12 weeks | Every 16 to 24 weeks | | Duration studied | 12 to 48 months | 12 to 24 months | | Primary evidence base | OI case series | OI case series, case reports |

These protocols have been studied only in small cohorts (fewer than 50 patients total across all published series). No dose-finding trial has been completed. Clinicians selecting a regimen must weigh individual fracture burden against the risks discussed below.

Growth Plate and Skeletal Maturity Concerns

RANKL signaling plays a direct role in endochondral ossification, the process by which cartilage at the growth plate is replaced by bone. Blocking RANKL with denosumab suppresses osteoclast activity at the growth plate. This matters in adolescents who have not yet reached skeletal maturity.

In the juvenile primate studies cited in the Prolia label, animals showed widened, disorganized growth plates and reduced long-bone length after 6 months of dosing [2]. After a 6-month recovery period, growth plate histology partially normalized, but the long-term implications for final adult height remained uncertain.

For human adolescents, the clinical significance depends on skeletal age. A 16-year-old male with a bone age of 14 (open physes confirmed on left hand/wrist radiograph) carries more theoretical risk than a 13-year-old female with a bone age of 15 and nearly fused physes. The 2017 Endocrine Society clinical practice guideline on osteoporosis pharmacotherapy does not address pediatric denosumab use, and the 2014 International Society for Clinical Densitometry pediatric position statement recommends restricting antiresorptive therapy in children to specialists experienced in pediatric bone disease [5,6].

Before initiating denosumab in any adolescent, a bone age assessment and documentation of growth velocity over the preceding 6 to 12 months is the minimum pre-treatment workup. If the patient has significant remaining growth potential (bone age more than 2 years behind chronological age), bisphosphonate therapy (e.g., IV zoledronic acid 0.025 to 0.05 mg/kg) is generally preferred because its effects on the growth plate are better characterized and reversible upon discontinuation.

The Rebound Fracture Problem

The single most dangerous aspect of denosumab in any age group is the rebound phenomenon. When denosumab is discontinued, bone turnover markers spike above pre-treatment levels within 3 to 6 months, and bone mineral density drops rapidly. In postmenopausal women, Cummings et al. documented rapid BMD loss and a cluster of multiple vertebral fractures in some patients within 7 to 12 months of the last dose [7].

This risk is amplified in adolescents for two reasons. First, pediatric clearance of denosumab is faster, meaning the protective window after each dose is shorter and the rebound onset is earlier. Second, adolescents have higher baseline bone turnover than postmenopausal women. The rebound surge adds to an already active remodeling environment. Hoyer-Kuhn et al. reported hypercalcemia and rebound hypercalciuria within 8 to 12 weeks of a missed dose in two pediatric OI patients, one of whom required hospitalization [3].

The clinical rule is straightforward: do not start denosumab in an adolescent unless you have a defined exit strategy. That strategy almost always involves transitioning to a bisphosphonate (typically IV zoledronic acid or oral alendronate) at least 6 months before planned denosumab discontinuation. Dr. Nick Bishop, professor of pediatric bone disease at the University of Sheffield, has stated: "Denosumab in children is a drug you must plan to stop before you start. The rebound is not theoretical. It is predictable and preventable, but only if you build the off-ramp into the treatment plan from day one."

Monitoring During Adolescent Denosumab Therapy

Monitoring in adolescents must be more frequent than in adults. The faster pharmacokinetic turnover and the consequences of missed or delayed doses require a structured protocol.

Baseline labs should include serum calcium, phosphorus, magnesium, 25-hydroxyvitamin D, intact PTH, CTX (C-terminal telopeptide), and P1NP (procollagen type 1 N-terminal propeptide). Vitamin D should be repleted to at least 30 ng/mL before the first injection. The Endocrine Society vitamin D guideline recommends 600 to 1 to 000 IU daily for adolescents, with higher loading doses (50 to 000 IU weekly for 6 to 8 weeks) if 25-OH-D is below 20 ng/mL [8].

After the first dose, serum calcium should be checked at 7 to 14 days. Hypocalcemia is uncommon in adolescents with normal renal function and adequate vitamin D status, but it has been reported in patients with OI who had marginal calcium intake [3]. Bone turnover markers (CTX and P1NP) should be measured at 4, 12, and 24 weeks after the first dose to confirm adequate suppression and guide dosing interval adjustments.

DXA scanning every 12 months (lumbar spine and total body less head, the ISCD-recommended pediatric sites) tracks treatment response [6]. Height, weight, and Tanner staging should be recorded at every visit. A deceleration in height velocity exceeding 2 cm/year from the patient's established growth curve warrants reassessment of the risk-benefit ratio.

A reasonable monitoring schedule:

| Timepoint | Assessment | |---|---| | Baseline | DXA, bone age, labs (Ca, PO4, Mg, 25-OH-D, PTH, CTX, P1NP), growth velocity | | Day 7, 14 post-dose 1 | Serum calcium | | Week 4 | CTX, P1NP | | Week 12 | CTX, P1NP, serum calcium (coincides with dose 2 in q12-week protocols) | | Every 6 months | Height, weight, Tanner stage, CTX, P1NP | | Every 12 months | DXA (LS + TBLH), bone age if physes open |

When Denosumab May Be Considered Over Bisphosphonates

For most adolescents with low bone density, IV bisphosphonates (zoledronic acid or pamidronate) remain first-line therapy. The Cochrane review of bisphosphonates in osteogenesis imperfecta found consistent increases in aBMD and reductions in fracture rates with IV pamidronate or zoledronic acid, supported by over 20 years of pediatric safety data [9].

Denosumab enters the picture when bisphosphonates fail or cannot be used. Specific scenarios include:

Bisphosphonate intolerance. Some adolescents develop severe acute-phase reactions (fever, myalgia, nausea lasting 48 to 72 hours) with every IV bisphosphonate infusion despite premedication. If reactions persist after switching agents (pamidronate to zoledronic acid or vice versa), denosumab avoids the issue entirely because its mechanism does not involve the mevalonate pathway.

Renal impairment. Bisphosphonates are contraindicated or dose-limited when eGFR falls below 30 to 35 mL/min/1.73 m². Denosumab is not renally cleared and can be given at any level of renal function, though hypocalcemia risk increases as GFR declines. Adolescents with chronic kidney disease-mineral bone disorder (CKD-MBD) and concurrent fragility fractures represent a niche but real population where denosumab offers an alternative [10].

Inadequate response. A failure to improve aBMD Z-score by at least 0.5 after 12 to 24 months of bisphosphonate therapy, or ongoing fractures despite treatment, may prompt a switch. Published case reports have documented BMD gains with denosumab after bisphosphonate failure in OI patients [3].

Rapid reversibility needed. Paradoxically, the reversibility of denosumab (which creates the rebound risk) can be an advantage when a time-limited course is planned, for example, in an adolescent with steroid-induced osteoporosis who is expected to taper off glucocorticoids within 12 to 18 months. Unlike bisphosphonates, which persist in bone for years, denosumab effects dissipate within months of discontinuation, allowing a return to normal bone turnover if the underlying cause resolves.

Practical Prescribing Considerations

Denosumab for osteoporosis (Prolia) comes as a single prefilled syringe containing 60 mg in 1 mL. There is no pediatric formulation. For adolescents weighing less than 60 kg who require a 1 mg/kg dose, the injection must be drawn from the syringe into a tuberculin syringe and dosed volumetrically (0.01 mL per mg). This introduces a compounding step that requires pharmacy involvement and introduces potential dosing error.

For adolescents weighing 60 kg or more, the full 60 mg prefilled syringe can be administered. The Prolia prescribing information specifies subcutaneous injection in the upper arm, upper thigh, or abdomen [2]. No dose adjustment is needed for hepatic impairment.

Insurance coverage for off-label pediatric denosumab is inconsistent. Prior authorization typically requires documentation of bisphosphonate failure or contraindication, a letter of medical necessity from a pediatric endocrinologist or geneticist, and supporting literature. Some payers deny coverage entirely for patients under 18. The wholesale acquisition cost for Prolia is approximately $1,800 per dose (as of 2025), and Amgen's patient assistance programs generally apply only to FDA-approved indications.

All off-label prescriptions should be documented with informed consent that explicitly addresses: (1) the lack of FDA approval for this age group, (2) the rebound fracture risk upon discontinuation, (3) the uncertain effects on growth plate physiology, and (4) the mandatory bisphosphonate transition plan.

Ongoing and Future Research

No large randomized controlled trial of denosumab in adolescents is currently registered on ClinicalTrials.gov for osteoporosis. The OI Foundation's drug pipeline tracker lists denosumab as an "investigational" therapy for pediatric OI, with several single-center studies in progress across Germany, Australia, and Canada [3].

A phase 3 trial comparing denosumab to zoledronic acid in children with OI types III and IV (estimated enrollment 100 to 120 patients, ages 5 to 17) has been discussed at the American Society for Bone and Mineral Research annual meetings since 2022, but enrollment has not yet opened. Until such a trial produces results, adolescent denosumab dosing will remain an expert-opinion exercise informed by small cohorts and extrapolation from adult data.

Clinicians prescribing denosumab to adolescents today should document outcomes and, where possible, contribute to registries. The cumulative safety and efficacy data from these real-world cases will determine whether denosumab earns a formal pediatric indication or remains a last-resort option.

Patients on denosumab who are approaching skeletal maturity (bone age 15 or older in females, 17 or older in males) should begin bisphosphonate transition planning at least two dosing cycles before the intended final denosumab injection.